Low expression of the CCL5 gene and low serum concentrations of CCL5 in severe invasive group a streptococcal disease

被引:0
|
作者
Kailankangas, V [1 ,2 ]
Katayama, S. [3 ,4 ,5 ]
Grondahl-Yli-Hannuksela, K. [6 ]
Vilhonen, J. [7 ]
Tervaniemi, M. H. [3 ,4 ]
Rantakokko-Jalava, K. [6 ,9 ]
Seiskari, T. [10 ]
Lonnqvist, E. [10 ]
Kere, J. [3 ,4 ,5 ]
Oksi, J. [7 ,8 ]
Syrjanen, J. [1 ,2 ]
Vuopio, J. [6 ,9 ,11 ]
机构
[1] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland
[2] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland
[3] Folkhalsan Res Ctr, Helsinki, Finland
[4] Univ Helsinki, Stem Cells & Metab Res Program, Helsinki, Finland
[5] Karolinska Inst, Dept Biosci & Nutr, Solna, Sweden
[6] Univ Turku, Inst Biomed, Turku, Finland
[7] Turku Univ Hosp, Dept Infect Dis, Turku, Finland
[8] Univ Turku, Fac Med, Turku, Finland
[9] Turku Univ Hosp, Dept Clin Microbiol, Lab Div, Turku, Finland
[10] Fimlab Labs, Dept Clin Microbiol, Tampere, Finland
[11] Finnish Inst Hlth & Welf THL, Helsinki, Finland
基金
芬兰科学院;
关键词
Streptococcus group A; Sepsis; Transcriptome; Streptococcal infections; Critical care; SEPSIS;
D O I
10.1007/s15010-024-02318-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose Our objective was to elucidate host dependent factors of disease severity in invasive group A Streptococcal disease (iGAS) using transcriptome profiling of iGAS cases of varying degrees of severity at different timepoints. To our knowledge there are no previous transcriptome studies in iGAS patients. Methods We recruited iGAS cases from June 2018 to July 2020. Whole blood samples for transcriptome analysis and serum for biomarker analysis were collected at three timepoints representing the acute (A), the convalescent (B) and the post-infection phase (C). Gene expression was compared against clinical traits and disease course. Serum chemokine ligand 5 (CCL5, an inflammatory cytokine) concentration was also measured. Results Forty-five patients were enrolled. After disqualifying degraded or impure RNAs we had 34, 31 and 21 subjects at timepoints A, B, and C, respectively. Low expression of the CCL5 gene correlated strongly with severity (death or need for intensive care) at timepoint A (AUC = 0.92), supported by low concentrations of CCL5 in sera. Conclusions Low gene expression levels and low serum concentration of CCL5 in the early stages of an iGAS infection were associated with a more severe disease course. CCL5 might have potential as a predictor of disease severity. Summary Low expression of genes of cytotoxic immunity, especially CCL5, and corresponding low serum concentrations of CCL5 associated with a severe disease course, i.e. death, or need for intensive care, in early phase of invasive group A Streptococcal disease.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 50 条
  • [31] Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples
    Kester, Maartje I.
    van der Flier, Wiesje M.
    Visser, Allerdien
    Blankenstein, Marinus A.
    Scheltens, Philip
    Oudejans, Cees B.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (01) : 61 - 65
  • [32] Prognostic and Predictive Potential of CCL5 Expression in Muscle-Invasive Bladder Cancer Patients
    Smolka, Cedric
    Eckstein, Markus
    Jung, Rudolf
    Lieb, Verena
    Sikic, Danijel
    Stoehr, Robert
    Bahlinger, Veronika
    Bertz, Simone
    Kehlen, Astrid
    Hartmann, Arndt
    Wullich, Bernd
    Taubert, Helge
    Wach, Sven
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
  • [33] CCL5/RANTES Gene Polymorphisms in Slavonic Patients with Myocardial Infarction
    Tereshchenko, Irina P.
    Petrkova, Jana
    Voevoda, Mikhail I.
    Taborsky, Milos
    Navratilova, Zdenka
    Romaschenko, Aida G.
    Maksimov, Vladimir N.
    Mrazek, Frantisek
    Petrek, Martin
    MEDIATORS OF INFLAMMATION, 2011, 2011
  • [34] The CCL5/CCR5 Axis in Cancer Progression
    Aldinucci, Donatella
    Borghese, Cinzia
    Casagrande, Naike
    CANCERS, 2020, 12 (07) : 1 - 30
  • [35] Expression and function of CCL5 and GPR75 in islets of Langerhans
    Liu, B.
    Hassan, Z.
    Amisten, S.
    Stubbert, D.
    King, A.
    Jones, P. M.
    Persaud, S. J.
    DIABETOLOGIA, 2011, 54 : S167 - S168
  • [36] Redox Sensitivity of Microrna-302 Regulation of CCL5 Expression
    Kumar, Maneesh G.
    Nicholson, Adam M.
    Kalen, Amanda L.
    Sarsour, Ehab H.
    Goswami, Prabhat C.
    FREE RADICAL BIOLOGY AND MEDICINE, 2011, 51 : S14 - S14
  • [37] Expression and purification of recombinant human CCL5 and its biological characterization
    Ma, Zhenling
    Zhang, Jiajia
    Wang, Lei
    Liu, Yiying
    Wang, Yunpeng
    Liu, Wei
    Xing, Guozhen
    Cheng, Kun
    Zheng, Wenming
    Xiang, Li
    PROTEIN JOURNAL, 2022, 41 (02): : 337 - 344
  • [38] Human CCL5 trimer: expression, purification and initial crystallographic studies
    Chen, Yi-Chen
    Li, Kun-Mou
    Zarivach, Raz
    Sun, Yuh-Ju
    Sue, Shih-Che
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2018, 74 : 82 - 85
  • [39] EMSY is increased and activates TSLP & CCL5 expression in eosinophilic esophagitis
    Fahey, Lisa M.
    Guzek, Ryan
    Ruffner, Melanie A.
    Sullivan, Kathleen E.
    Spergel, Jonathan
    Cianferoni, Antonella
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2018, 29 (05) : 565 - 568
  • [40] The CCL2 and CCL5 chemokine levels in serum of multiple sclerosis patients during relapse
    Bartosik-Psujek, H
    Stelmasiak, Z
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S169 - S169